

## Supplementary Information for:

### Immunogenicity of a novel tetravalent vaccine formulation with four recombinant lipidated dengue envelope protein domain IIIs in mice

Chen-Yi Chiang<sup>1,†</sup>, Chien-Hsiung Pan<sup>1,2,†</sup>, Mei-Yu Chen<sup>1</sup>, Chun-Hsiang Hsieh<sup>1</sup>, Jy-Ping Tsai<sup>1</sup>, Hsueh-Hung Liu<sup>1</sup>, Shih-Jen Liu<sup>1,2</sup>, Pele Chong<sup>1,2</sup>, Chih-Hsiang Leng<sup>1,2,\*</sup> and Hsin-Wei Chen<sup>1,2,\*</sup>

<sup>1</sup>National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, 35 Keyan Road, Zhunan, Miaoli 350, Taiwan, Republic of China

<sup>2</sup>Graduate Institute of Immunology, China Medical University, Taichung, Taiwan, Republic of China

\***Corresponding authors:** Hsin-Wei Chen, E-mail: [chenhw@nhri.org.tw](mailto:chenhw@nhri.org.tw), Tel: 886-3-724-6166 ext 37706, Fax: 886-3-758-3009 or Chih-Hsiang Leng, E-mail: [leoleng@nhri.org.tw](mailto:leoleng@nhri.org.tw), Tel: 886-3-724-6166 ext 37711, Fax: 886-3-758-3009

†these authors contributed equally to this work.

#### Contents:


Supplementary Table S1

Supplementary Figure S1

Supplementary Table S1. Neutralizing antibody titers (FRNT<sub>70</sub>) in mice immunized with monovalent formulations.

	Vaccine			
	LD1ED III	LD2ED III	LD3ED III	LD4ED III
Dengue-1	2 <sup>5</sup> , 2 <sup>3</sup> , 2 <sup>4</sup> , 2 <sup>4</sup> , 2 <sup>5</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>
Dengue-2	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	2 <sup>10</sup> , 2 <sup>9</sup> , 2 <sup>7</sup> , 2 <sup>7</sup> , 2 <sup>7</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>
Dengue-3	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	2 <sup>4</sup> , <2 <sup>3</sup> , 2 <sup>3</sup> , 2 <sup>3</sup> , 2 <sup>5</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>
Dengue-4	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	<2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup>	2 <sup>3</sup> , 2 <sup>3</sup> , <2 <sup>3</sup> , <2 <sup>3</sup> , 2 <sup>3</sup>

Supplementary Figure S1.



**Supplementary Figure S1. Induction of antibody responses against 4 serotypes of dengue virus in mice immunized with a monovalent or tetravalent recombinant lipidated dengue envelope protein domain IIIs.**

Groups of BALB/c mice (n=5-6) were immunized subcutaneously twice with a monovalent vaccine (10  $\mu$ g recombinant lipidated dengue envelope protein domain III), a tetravalent vaccine (10  $\mu$ g of each serotype of recombinant lipidated dengue envelope protein domain III) or PBS at a 4-week interval. Serum samples were collected at 8 weeks after the first immunization. IgG antibodies against dengue-1, dengue-2, dengue-3 and dengue-4 virus were evaluated by ELISA, respectively. Data represent mean  $\pm$  standard deviation. Dashed lines indicate 2-fold of mean background levels (OD<sub>450nm</sub>= 0.2).